VRTX vs. AMGN, REGN, GILD, AGN, ALXN, BIIB, ALNY, RPRX, BMRN, and BGNE
Should you be buying Vertex Pharmaceuticals stock or one of its competitors? The main competitors of Vertex Pharmaceuticals include Amgen (AMGN), Regeneron Pharmaceuticals (REGN), Gilead Sciences (GILD), Allergan (AGN), Alexion Pharmaceuticals (ALXN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Royalty Pharma (RPRX), BioMarin Pharmaceutical (BMRN), and BeiGene (BGNE).
Amgen (NASDAQ:AMGN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings, valuation and community ranking.
76.5% of Amgen shares are owned by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. 0.7% of Amgen shares are owned by company insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Amgen has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500.
Amgen has higher revenue and earnings than Vertex Pharmaceuticals. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.
Vertex Pharmaceuticals has a net margin of 39.46% compared to Vertex Pharmaceuticals' net margin of 12.74%. Vertex Pharmaceuticals' return on equity of 156.21% beat Amgen's return on equity.
Vertex Pharmaceuticals received 30 more outperform votes than Amgen when rated by MarketBeat users. Likewise, 75.63% of users gave Vertex Pharmaceuticals an outperform vote while only 72.41% of users gave Amgen an outperform vote.
In the previous week, Vertex Pharmaceuticals had 10 more articles in the media than Amgen. MarketBeat recorded 31 mentions for Vertex Pharmaceuticals and 21 mentions for Amgen. Vertex Pharmaceuticals' average media sentiment score of 1.03 beat Amgen's score of 0.83 indicating that Amgen is being referred to more favorably in the media.
Amgen currently has a consensus price target of $305.65, indicating a potential upside of 0.21%. Vertex Pharmaceuticals has a consensus price target of $438.62, indicating a potential downside of 9.20%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Amgen is more favorable than Vertex Pharmaceuticals.
Summary
Amgen and Vertex Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks.
Get Vertex Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vertex Pharmaceuticals Competitors List
Related Companies and Tools
